Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia

Blood

Volumn 120, Issue 7, 2012, Pages 1529-1531

  Lierman, Els ^a   Selleslag, Dominik ^b   Smits, Sanne ^c   Billiet, Johan ^b   Vandenberghe, Peter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b AZ Sint Jan   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; HYDROXYUREA; JANUS KINASE 2; RUXOLITINIB; STAT5 PROTEIN; TRANSCRIPTION FACTOR ETV6;

AGED; ANEMIA; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 8P; CHROMOSOME 9P; CHROMOSOME BREAKAGE; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG DOSE INCREASE; ENZYME PHOSPHORYLATION; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; ERYTHROCYTE TRANSFUSION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE SEQUENCE; GRANULOCYTE PRECURSOR; HUMAN; IC 50; IN VITRO STUDY; KARYOTYPE 46,XY; LETTER; LEUKEMIA REMISSION; MALE; METAPHASE; MOLECULAR CLONING; MYELOID PROGENITOR CELL; MYELOPOIESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTOPENIA; WESTERN BLOTTING;

EID: 84865188297     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-433821     Document Type: Letter

References (8)

1. Hoeller S, Walz C, Reiter A, Dirnhofer S, Tzankov A. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms. Expert Opin Ther Targets. 2011;15(1):53-62.
2. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65(7):2662-2667.
3. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278(5341):1309- 1312.
4. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15:12) in a myeloid leukemia. Blood. 1997;90(7):2535-2540.
5. Van Roosbroeck K, Cox L, Tousseyn T, et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood. 2011;117(15):4056-4064.
6. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
7. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787-798.
8. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.